(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-1.85% $ 273.30
Live Chart Being Loaded With Signals
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally...
Stats | |
---|---|
Volumen de hoy | 713 845 |
Volumen promedio | 724 103 |
Capitalización de mercado | 132.07B |
EPS | $0 ( 2024-02-13 ) |
Last Dividend | $1.621 ( 2023-03-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 34.86 |
ATR14 | $0.0970 (0.04%) |
Volumen Correlación
CSL Ltd Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CSL Ltd Correlación - Moneda/Commodity
CSL Ltd Finanzas
Annual | 2023 |
Ingresos: | $19.59B |
Beneficio Bruto: | $9.47B (48.33 %) |
EPS: | $6.92 |
FY | 2023 |
Ingresos: | $19.59B |
Beneficio Bruto: | $9.47B (48.33 %) |
EPS: | $6.92 |
FY | 2022 |
Ingresos: | $14.47B |
Beneficio Bruto: | $7.68B (53.05 %) |
EPS: | $6.63 |
FY | 2021 |
Ingresos: | $10.27B |
Beneficio Bruto: | $5.80B (56.49 %) |
EPS: | $5.22 |
Financial Reports:
No articles found.
CSL Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$1.758 (N/A) |
$0 (N/A) |
$1.621 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0167 | 1994-11-08 |
Last Dividend | $1.621 | 2023-03-09 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 59 | -- |
Total Paid Out | $28.07 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.48 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.26 | |
Div. Directional Score | 9.64 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
YAL.AX | Ex Dividend Knight | 2023-09-05 | Annually | 0 | 0.00% | |
FGG.AX | Ex Dividend Junior | 2023-10-05 | Annually | 0 | 0.00% | |
PMV.AX | Ex Dividend Knight | 2023-06-20 | Semi-Annually | 0 | 0.00% | |
ARG.AX | Ex Dividend Knight | 2023-08-25 | Semi-Annually | 0 | 0.00% | |
IFL.AX | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
SDG.AX | Ex Dividend Knight | 2023-10-24 | Quarterly | 0 | 0.00% | |
CCP.AX | Ex Dividend Knight | 2023-09-18 | Annually | 0 | 0.00% | |
MCY.AX | Ex Dividend Knight | 2023-09-13 | Semi-Annually | 0 | 0.00% | |
TGF.AX | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
CUV.AX | Ex Dividend Knight | 2023-09-05 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.180 | 1.500 | 6.41 | 9.61 | [0 - 0.5] |
returnOnAssetsTTM | 0.0696 | 1.200 | 7.68 | 9.21 | [0 - 0.3] |
returnOnEquityTTM | 0.156 | 1.500 | 9.38 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.450 | -1.000 | 5.50 | -5.50 | [0 - 1] |
currentRatioTTM | 2.15 | 0.800 | 4.25 | 3.40 | [1 - 3] |
quickRatioTTM | 0.971 | 0.800 | 9.00 | 7.20 | [0.8 - 2.5] |
cashRatioTTM | 0.216 | 1.500 | 9.91 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.282 | -1.500 | 5.30 | -7.95 | [0 - 0.6] |
interestCoverageTTM | 6.97 | 1.000 | 8.53 | 8.53 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.34 | 2.00 | 7.22 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.59 | 2.00 | 8.21 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.612 | -1.500 | 7.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.484 | 1.000 | 5.26 | 5.26 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.244 | 1.000 | 7.12 | 7.12 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.261 | 1.000 | 9.66 | 9.66 | [0.2 - 2] |
assetTurnoverTTM | 0.388 | 0.800 | -0.748 | -0.599 | [0.5 - 2] |
Total Score | 12.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.66 | 1.000 | 6.60 | 0 | [1 - 100] |
returnOnEquityTTM | 0.156 | 2.50 | 9.60 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.59 | 2.00 | 8.80 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.393 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.34 | 2.00 | 7.22 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.450 | 1.500 | 5.50 | -5.50 | [0 - 1] |
pegRatioTTM | 7.92 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.190 | 1.000 | 7.75 | 0 | [0.1 - 0.5] |
Total Score | 7.26 |
CSL Ltd
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico